Trial Profile
A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adavosertib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Cervical intraepithelial neoplasia; Head and neck cancer; Ovarian cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Feb 2020 Safety results published in the Targeted Oncology.
- 09 Nov 2017 Status changed from active, no longer recruiting to completed.
- 30 Oct 2017 Results assessing safety presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.